ArticleAntibiotics (Basel, Switzerland)2025
Epidemiology of Carbapenem-Resistant Klebsiella Pneumoniae Co-Producing MBL and OXA-48-Like in a Romanian Tertiary Hospital: A Call to Action.
Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Ceftazidime-Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis.Microorganisms · 2026Article
- Carbapenem-ResistantMicroorganisms · 2026Review
- Antimicrobial Resistance Profile ofAntibiotics (Basel, Switzerland) · 2026Article
- Incidence of carbapenemase-resistant isolates ofNew microbes and new infections · 2026Article
- Phylogenetic Relationships and Structural Conservation ofInternational journal of molecular sciences · 2026Article
- Emergence of ST383 carbapenem-resistantJAC-antimicrobial resistance · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Genomic characterization ofFrontiers in microbiology · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Editorial: ESKAPEing host endogenous and exogenous defenses: new insights into the ability of multidrug- resistant bacteria to overcome host defenses and antimicrobial compounds activity.Frontiers in cellular and infection microbiology · 2026Article
- Diversity in Carbapenemases in Enterobacterales in Southeastern Austria Before and During the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2025Article
- Significant Prevalence of Dual KPC/NDM Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Distribution of MBL and serine-β-lactamase-producing pathogens in ventilator-associated pneumonia: insights into MDR and XDR strains.Iranian journal of microbiology · 2025Article
- Insights intoFrontiers in microbiology · 2025Article
- In Vitro Activity of Ceftazidime/Avibactam Against Multidrug-Resistant Gram-Negative Bacilli in Niger.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.